AbbVie: Why I See More Upside After Q3
AbbVie has more upside following its Q3 results
View original →Cite asCryptoQuant has tracked the directional calls on ABBV by @allka-research on Seeking Alpha since Jun 2024: not yet scored on ABBV (as of Nov 18, 2026).
2 ABBV calls on record, a thin history.
Relative view by default: fewer than 30 ABBV calls or days on record.
Sentiment timeline shows relative sentiment within this analyst's history. A perma-bull showing 8 bullish : 2 bearish in a bear market sets that as their baseline. If you notice any errors, claim @seekingalpha:allka-research to submit corrections.
Hover the chart to read the thesis of that period · click a day to pin it
AbbVie: Why I See More Upside After Q3
AbbVie has more upside following its Q3 results
View original →Eli Lilly: Mounjaro And Zepbound Keep The Growth Story Alive
View original →BeOne Medicines: Brukinsa And Tevimbra Face A High Bar
View original →Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs
Adding dividend yield and forward P/E, Pfizer offers one of the most appealing risk/reward profiles.
View original →AbbVie: Strong Q2 And New Catalysts Keep Me Bullish
Faster-than-expected growth in immunology, neuroscience and oncology, plus dividend and Apogee deal, justify Buy.
View original →